Race to deliver therapies directly to the heart

Overview

Updated May 27

In March 2026, the FDA accepted BioCardia's pre-submission package for the Helix Transendocardial Delivery Catheter, the first catheter that injects cell and gene therapies directly into heart muscle, and scheduled a formal meeting for Q2 2026. The device, backed by fifteen clinical trials, uses a small helical needle anchored within the beating heart to precisely deliver therapeutic agents to damaged tissue; CDRH leads the review in consultation with CBER.

BioCardia is pursuing two regulatory tracks: alongside the Helix device review, it submitted CardiAMP Heart Failure trial data to the FDA in April 2026 and requested a Q2 meeting to explore accelerated approval for CardiAMP, a therapy using bone marrow cells to repair heart tissue. Echocardiography data from March's Technology and Heart Failure Therapeutics conference in Boston showed the therapy reduces pathological left ventricular remodeling, a sign the heart is rebuilding rather than deteriorating further. The company ended 2025 with approximately $2.5 million in cash and no revenues.

Why it matters

Clearing the delivery device would unlock an entire generation of cardiac cell and gene therapies for the 6 million Americans living with heart failure.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

Clinical trials supporting approval

BioCardia's FDA submission includes safety and efficacy data from fifteen controlled studies

425,147

Annual U.S. deaths involving heart failure

Heart failure contributed to nearly half of all cardiovascular deaths in 2022

11%

Cell retention with intramyocardial delivery

Direct injection retains nearly four times more cells than intracoronary delivery

47%

Reduction in heart death equivalents

BioCardia's CardiAMP therapy showed this reduction in phase 3 trial results

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Peter Altman

President, Chief Executive Officer & Co-Founder, BioCardia

Leading dual regulatory tracks for Helix catheter and CardiAMP therapy

Simon Stertzer

Co-Founder, BioCardia

Founding contributor

Amish Raval

CardiAMP HF Trial National Co-Principal Investigator; Professor of Medicine, University of Wisconsin School of Medicine and Public Health

Presented late-breaking trial results at THT 2026

Organizations Involved

BioCardia, Inc.

Biotechnology Company

FDA Q2 meetings scheduled for both Helix catheter review and CardiAMP accelerated approval; $2.5M cash at year-end 2025

BioCardia develops biotherapeutic delivery systems and cell therapies for cardiovascular disease, headquartered in San Carlos, California.

U.S. Food and Drug Administration

Federal regulatory agency

Accepted Helix pre-submission for substantive review; Q2 2026 meeting scheduled; reviewing CardiAMP accelerated approval request

The FDA regulates medical devices, drugs, and biologics in the United States, including cell and gene therapies for cardiac disease.

Biosense Webster

Medical Device Company (Johnson & Johnson)

Competitor with NOGA/MyoStar system

Biosense Webster develops cardiac mapping and ablation technologies, including the MyoStar injection catheter used in early cell therapy research.

Timeline

January 1999 April 2026

13 events Latest: April 28th, 2026 · 5 months ago Showing 8 of 13

Tap a bar to jump to that date

April 2026
Japanese Patent Allowed for Heart3D Fusion Imaging Software
Latest Corporate

Japan allows BioCardia's patent covering its Heart3D Fusion Imaging software used for procedure planning and real-time navigation during CardiAMP procedures; BioCardia reports positive consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on a potential approval submission.
April 28th, 2026
BioCardia Files for FDA Meeting on CardiAMP Accelerated Approval
Regulatory

BioCardia submits CardiAMP HF clinical study data to FDA and requests a Q2 2026 meeting to discuss the accelerated approval pathway for the CardiAMP System in ischemic heart failure with reduced ejection fraction, under its Breakthrough Designation.
April 2nd, 2026
March 2026
BioCardia Reports 2025 Annual Results with $2.5M Cash
Corporate

BioCardia reports 2025 annual financial results: net loss of $8.2 million, R&D expenses of $5.0 million, zero revenues, and cash of approximately $2.5 million at year-end.
March 24th, 2026
FDA Accepts Helix Pre-Submission Package for Substantive Review
Regulatory

FDA accepts BioCardia's Helix Transendocardial Delivery Catheter pre-submission package, confirming it contains all necessary elements for substantive review; formal Q2 2026 review meeting scheduled; CDRH leads in consultation with CBER.
March 17th, 2026
CardiAMP Echocardiography Data Presented at THT Conference
Clinical Trial

Late-breaking echocardiography results from the CardiAMP HF trial presented at Technology and Heart Failure Therapeutics (THT) in Boston show cell therapy patients demonstrated statistically significant reductions in pathological left ventricular remodeling versus controls, particularly in the elevated-biomarker subgroup.
March 3rd, 2026
February 2026
FDA Pre-Submission Filed for Helix Catheter
Regulatory

BioCardia files Pre-Submission with FDA seeking approval of Helix Transendocardial Delivery Catheter, supported by data from 15 clinical trials under Breakthrough Designation.
February 10th, 2026
March 2025
Two-Year Trial Results Show 47% Reduction in Deaths
Clinical Trial

BioCardia announces two-year outcomes from Phase 3 CardiAMP-HF study showing 47% relative risk reduction in heart death equivalents and improved quality of life.
March 31st, 2025
October 2024
Phase 3 Trial Completed
Clinical Trial

BioCardia completes Phase 3 randomized double-blind controlled trial of autologous cell therapy for ischemic heart failure with 115 patients across 18 centers.
October 28th, 2024
August 2024
FDA Approves Protocol Amendment
Regulatory

FDA approves CardiAMP Heart Failure II protocol amendment to use proprietary cell population analysis screening to define treatment.
August 21st, 2024
March 2024
Positive Interim Phase 3 Results
Clinical Trial

BioCardia reports positive interim results from CardiAMP-HF trial showing 86% relative risk reduction in heart death equivalents in patients with elevated biomarkers.
March 1st, 2024
October 2016
BioCardia Goes Public
Corporate

BioCardia becomes a publicly traded company through a reverse merger with Tiger X Medical.
October 1st, 2016
January 2003
Early Transendocardial Injection Studies
Research

First clinical studies using catheter-based transendocardial injection of skeletal myoblasts in heart failure patients demonstrate feasibility of the approach.
January 1st, 2003
January 1999
BioCardia Founded
Corporate

Dr. Simon Stertzer and colleagues establish BioCardia in San Carlos, California, to develop biointerventional cardiology technologies.
January 1st, 1999

#timeline [x-show="expanded"] { display: revert !important; opacity: 1 !important; } #timeline .timeline-toggle-btn { display: none; }

Scenarios

FDA Approves First Cardiac Delivery Catheter, Unlocking New Therapies

Possible

Discussed by: BioCardia investor communications, regenerative medicine analysts at CGT Live and Cardiac Interventions Today

The FDA clears the Helix catheter within 12-18 months following Pre-Submission alignment. As the first approved transendocardial delivery system, it becomes the standard platform for delivering emerging cell and gene therapies to the heart, opening a new commercial market. Multiple pharmaceutical companies license the technology for their cardiac therapy pipelines.

FDA Requires Additional Clinical Data, Delaying Approval

Possible

Discussed by: Medical device regulatory consultants, FDA device approval process analysts

The FDA's Pre-Submission feedback identifies gaps in the existing clinical data, requiring BioCardia to conduct additional studies or provide supplementary safety analyses. This extends the timeline by 2-3 years but maintains the pathway to eventual approval. The company's limited cash position becomes a critical factor.

Competitor Reaches Market First with Alternative Delivery System

Unlikely

Discussed by: Cardiac device industry analysts, medical technology investors

Another company—potentially a larger player like Biosense Webster or a well-funded competitor—accelerates development of a competing transendocardial or alternative delivery system, reaching FDA approval before BioCardia. This would diminish Helix's first-mover advantage and compress its market opportunity.

Cardiac Gene Therapy Approval Creates Urgent Delivery Demand

Possible

Discussed by: Gene therapy developers, cardiology researchers at Circulation Research and Nature

One of the cardiac gene therapies currently in late-stage trials achieves FDA approval, creating immediate clinical need for a delivery mechanism. This external catalyst accelerates FDA review of the Helix catheter as an enabling technology, potentially through expedited review pathways.

BioCardia Runs Short on Cash Before FDA Decisions

Possible

Discussed by: Medical device analysts and biotech investors tracking BCDA financial filings

With approximately $2.5 million in cash at year-end 2025, no revenues, and two simultaneous FDA review processes underway, BioCardia faces a narrow financing window. If regulatory meetings extend without approval or a partnership deal, the company may need to raise dilutive capital or seek a strategic acquirer. A funding gap would jeopardize both the Helix catheter and CardiAMP approval tracks simultaneously.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1997-2005

Biosense Webster NOGA System Development (1997-2005)

Biosense Webster developed the NOGA electromechanical mapping system with the MyoStar injection catheter, creating the first commercial platform for targeted intramyocardial injection. The system could construct three-dimensional heart maps and guide needle placement to specific regions of damaged tissue.

Then

The technology enabled dozens of clinical trials investigating cell therapy for cardiac disease, establishing proof of concept for targeted delivery.

Now

While the NOGA/MyoStar system was never approved specifically as a therapy delivery device, it proved the technological foundation that BioCardia and others built upon.

Why this matters now

The Helix catheter is designed as a dedicated delivery system rather than a mapping tool with injection capability, representing a shift from research-focused devices to a commercial therapeutic platform.

June 2003

First Autologous Stem Cell Heart Injection (2003)

French surgeon Philippe Menasché performed the first clinical injection of autologous skeletal myoblasts into human heart muscle using catheter-based delivery. Five patients with ischemic heart failure received cells via the MyoStar NOGA-guided catheter system. The procedure demonstrated feasibility but raised questions about arrhythmia risks.

Then

The pilot study showed the approach was technically possible, with improvements in heart function observed at six-month follow-up.

Now

This pioneering work launched two decades of clinical trials exploring catheter-based cell delivery to the heart, establishing transendocardial injection as a viable approach despite ongoing safety refinements.

Why this matters now

BioCardia's Helix catheter represents the culmination of this 20+ year development arc—the first attempt to gain regulatory approval for a device category that has existed only in research settings.

2014-2022

REGENERATE Trials and Delivery Method Debate (2014-2022)

The REGENERATE-IHD and REGENERATE-DCM trials directly compared intracoronary delivery (through coronary arteries) versus intramyocardial delivery (directly into heart muscle) in 60+ patients with chronic heart failure. Researchers sought to determine whether the technically simpler intracoronary approach could match the cell retention of direct injection.

Then

Studies found intramyocardial injection retained about 11% of delivered cells versus 3% for intracoronary delivery—a significant difference for therapeutic efficacy.

Now

The data reinforced the clinical rationale for transendocardial delivery systems like Helix, demonstrating that the added procedural complexity produces meaningfully better cell retention.

Why this matters now

This body of evidence supports BioCardia's FDA application by showing that transendocardial delivery is not just one option among equals—it appears to be the superior approach for getting therapeutic cells where they need to go.